Personalised medicine and population health: breast and ovarian cancer.

Main|Search|PHGKB


Last Posted: Oct 20, 2018

---

• Personalised medicine and population health: breast and ovarian cancer.
  Narod Steven A et al. Human genetics 2018 Oct
• Contributions of Public Health in Reducing the Population Burden of Familial Hypercholesterolemia: Challenges and Opportunities
  MJ Khoury et al, CDC Blog Post, October 17, 2018
• Familial breast cancer and DNA repair genes: insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing.
  Girard Elodie et al. International journal of cancer 2018 Oct
• Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings.
  Bonache Sandra et al. Journal of cancer research and clinical oncology 2018 Oct
• Perspectives from a state genetics coordinator: Public health’s role in addressing familial hypercholesterolemia (FH) in the United States
  Deb Lochner Doyle, Blog Post, October 17, 2018
• Direct-to-consumer genetic testing for breast cancer risk.
  Reed E Kate et al. Journal of the American Association of Nurse Practitioners 2018 Oct 30(10) 548-550
• Changing landscape of hereditary breast and ovarian cancer germline genetic testing in Australia.
  Petelin Lara et al. Internal medicine journal 2018 Oct 48(10) 1269-1272
• Gynecological-endocrinological aspects in women carriers of BRCA1/2 gene mutations.
  Doren A et al. Climacteric : the journal of the International Menopause Society 2018 Oct 1-7
• [The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition].
  Moretta Jessica et al. Bulletin du cancer 2018 Sep
• Comprehensive Analysis of Germline Variants in Mexican Patients with Hereditary Breast and Ovarian Cancer Susceptibility.
  Quezada Urban Rosalía et al. Cancers 2018 Sep 10(10)

more